These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 8778197

  • 1. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies.
    Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartín P.
    J Hepatol; 1996 Mar; 24(3):308-12. PubMed ID: 8778197
    [Abstract] [Full Text] [Related]

  • 2. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S, Olmedo E, Maluenda MD, Forns X, López-Labrador FX, Costa J, Sánchez-Tapias JM, de Anta MT, Rodés J.
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [Abstract] [Full Text] [Related]

  • 3. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.
    Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, Cesana B, Lunghi G, Piperno A, Valsecchi C, Fiorelli G.
    Eur J Gastroenterol Hepatol; 1997 May; 9(5):497-503. PubMed ID: 9187884
    [Abstract] [Full Text] [Related]

  • 4. Clinical presentation of GB-C virus infection in drug abusers with chronic hepatitis C.
    Goeser T, Seipp S, Wahl R, Müller HM, Stremmel W, Theilmann L.
    J Hepatol; 1997 Mar; 26(3):498-502. PubMed ID: 9075655
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van Thiel DH.
    Hepatogastroenterology; 1997 Mar; 44(14):417-25. PubMed ID: 9164512
    [Abstract] [Full Text] [Related]

  • 6. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
    Mizokami M, Orito E, Gibo Y, Suzuki K, Ohba K, Ohno T, Lau JY.
    Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
    [Abstract] [Full Text] [Related]

  • 7. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
    Pawlotsky JM, Darthuy F, Rémiré J, Pellet C, Udin L, Stuyver L, Roudot-Thoraval F, Duvoux C, Douvin C, Mallat A.
    J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
    [Abstract] [Full Text] [Related]

  • 8. Steroid and interferon therapy in liver/kidney microsomal antibody-positive patients with chronic hepatitis C.
    Vento S, Cainelli F, Concia E, Ferraro T.
    J Hepatol; 1997 Apr; 26(4):955-6. PubMed ID: 9126815
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C, Carniello GS, Colle R, Doretto P, Mazzi G, Crovatto M, Santini GF, Tulissi P, Gregoretti M, Mazzoran L, Russo A, Silvestri F, Pozzato G.
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [Abstract] [Full Text] [Related]

  • 12. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A, Hussain MM, Aslam M, Hussain T, Butt IF, Ali Khan S, Asad A.
    J Ayub Med Coll Abbottabad; 2009 Aug; 21(2):103-6. PubMed ID: 20524482
    [Abstract] [Full Text] [Related]

  • 13. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L, Grassi G, Giacca M, Gerini U, Baracetti S, Fanni-Canelles M, Zorat F, Pozzato G.
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [Abstract] [Full Text] [Related]

  • 14. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.
    Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, Mayumi M.
    J Med Virol; 1994 Mar; 42(3):299-305. PubMed ID: 7516422
    [Abstract] [Full Text] [Related]

  • 15. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy.
    Van Thiel DH, Caraceni P, Molloy PJ, Hassanein T, Kania RJ, Gurakar A, Friedlander L.
    J Hepatol; 1995 Nov; 23(5):503-8. PubMed ID: 8583136
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment.
    Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R.
    Hepatology; 1994 Feb; 19(2):273-9. PubMed ID: 8294085
    [Abstract] [Full Text] [Related]

  • 17. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment.
    Orito E, Mizokami M, Suzuki K, Ohba KI, Ohno T, Mizuno M, Iijima Y, Saito H, Nemoto A, Nukuta N.
    J Gastroenterol Hepatol; 1997 Jan; 12(1):58-61. PubMed ID: 9076625
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.